Scholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of “Buy” by Analysts

Scholar Rock Holding Co. (NASDAQ:SRRK) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $42.67.

Separately, Wedbush restated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $26.90 on Monday. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $2.55 billion, a PE ratio of -11.45 and a beta of 0.56. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The stock’s 50-day simple moving average is $36.31 and its 200 day simple moving average is $34.01.

Insider Transactions at Scholar Rock

In related news, CEO Jay T. Backstrom sold 22,308 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $986,013.60. Following the transaction, the chief executive officer now owns 330,363 shares in the company, valued at $14,602,044.60. The trade was a 6.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at approximately $2,373,490. This trade represents a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock worth $11,245,798 over the last ninety days. 19.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC increased its position in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after buying an additional 1,031 shares during the period. GF Fund Management CO. LTD. bought a new position in Scholar Rock in the fourth quarter worth approximately $85,000. Finally, Amalgamated Bank grew its stake in Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after acquiring an additional 620 shares during the period. 91.08% of the stock is owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.